Skip to main content

Table 2 Summary of results*; gut barrier integrity markers, oxidation markers, inflammatory markers

From: Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects

Variable Ptreat Ptime Zeolite Placebo Zeolite Placebo Reference range
0 week 0 week 12 weeks 12 weeks
zonulin 0.006 >0.1 61.2 ± 11.0 56.1 ± 13.2 43.8 ± 14.3 59.6 ± 12.3 <55
ng . mL-1
α1-antitrypsin >0.1 >0.1 27.6 ± 14.8 32.8 ± 15.6 30.2 ± 18.1 35.8 ± 17.7 <37.5
mg . dL-1
CP >0.1 <0.001 218 ± 102 206 ± 98 508 ± 108 486 ± 87 80–200
pmol . mg-1
iPF2α-III >0.1 >0.1 216 ± 55 200 ± 55 199 ± 73 181 ± 43 50–400
pg . mL-1
GPx3 >0.1 <0.001 131 ± 69 107 ± 58 182 ± 64 193 ± 59 33–98
IU . L-1
DNA SB >0.1 >0.1 0.36 ± 0.25 0.35 ± 0.24 0.49 ± 0.33 0.48 ± 0.29 0–70
AU
TNF-α >0.1 0.024 26.1 ± 8.7 24.3 ± 12.3 31.8 ± 11.5 28.7 ± 11.8 0–69
pg . mL-1
IL-6 >0.1 >0.1 26.6 ± 2.0 27.1 ± 1.7 27.7 ± 3.2 26.9 ± 2.7 <100
pg . mL-1
IL-8 >0.1 >0.1 38.1 ± 10.8 41.9 ± 12.0 39.7 ± 11.5 39.8 ± 9.7 0–62
pg . mL-1
IL-10 0.087 >0.1 40.1 ± 19.2 42.1 ± 16.0 54.5 ± 27.8 37.9 ± 22.2 none
pg . mL-1
IL-22 >0.1 >0.1 42.9 ± 4.2 41.4 ± 3.3 40.5 ± 3.3 40.1 ± 4.4 none
pg . mL-1
  1. *Values are means ± SD; P < 0.05, ANOVA; n = 27 (Zeolite), n = 25 (Placebo); α1-antitrypsin alpha1-antitrypsin, CP carbonyl groups bounded on protein, iPF2α-III isoprostanes F2α-III, GPx3 plasma glutathione peroxidase, DNA SB DNA strand-breaks, TNF-α tumor necrose factor alpha, IL interleukin, treat treatment